Subscribe to our Newsletter
This session provides an in-depth overview of clinical criteria and biomarkers used to identify patients with early HR+ HER2- breast cancer who are at high risk of recurrence. Prof. Lambertini discusses risk stratification strategies and their implications for treatment planning.
